Novo Nordisk stock investors are eagerly awaiting the potential launch of its weight loss treatment in oral form.

AI-generated source summary

Novo Nordisk (NVO) stock decreased by 4.6% on Thursday, September 25th. The company lowered its full-year outlook for 2025 compared to the outlook issued in May. For 2025, the range for sales growth is now expected to be 8% to 14% at constant exchange rates or 11% at the midpoint. The reasons for lowering growth expectations are based on lower growth expectations for VIGOVI and Ozempic in the U. S. obesity market and the U. S. GLP-one market, persistent use of compounded GLP-one, and slower market expansion and competition. Despite the expiry of the FDA grace period for mass compounding on 05/22/2025, Novo Nordisk market research shows that the unsafe and unlawful mass compounding has continued, resulting in multiple providers continuing to market and sell compounded GLP-1s. In response, Novo Nordisk is pursuing litigation to protect patients. There is an expectation to launch an oral version, or pill version, in the next few months. The presenter increased the intrinsic value per share to $136.67. The actual price is $56.04

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   27 Sept 2025, 15:45 UTC

   The analyst published the original source item.

2. First prediction resolved

   30 Oct 2025, 13:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   30 Oct 2025, 13:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:13 UTC

   Tahlil Plus began monitoring the extracted predictions.